-
*Kazuto Watanabe
ICH-M3 Task Force (Chronic Tox Sub-working Group), Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures Association Chugai Pharmaceutical Co., Ltd.
-
Eiji Hosoki
ICH-M3 Task Force (Chronic Tox Sub-working Group), Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures Association Otsuka Pharmaceutical Co., Ltd.
-
Hajime Matsui
ICH-M3 Task Force (Chronic Tox Sub-working Group), Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures Association The Chemo-Sero-Therapeutic Research Institute
-
Syuji Ogawa
ICH-M3 Task Force (Chronic Tox Sub-working Group), Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures Association Zeria Pharmaceutical Co., Ltd.
-
Mitsuru Kobayashi
ICH-M3 Task Force (Chronic Tox Sub-working Group), Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures Association Teijin Pharma Limited
-
Keiji Yamamoto
ICH-M3 Task Force (Chronic Tox Sub-working Group), Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures Association Takeda Pharmaceutical Co., Ltd.
-
Fumio Sagami
ICH-M3 Task Force (Chronic Tox Sub-working Group), Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures Association Eisai Co., Ltd.
